Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00108082 |
This study is designed to compare the effects of COREG MR (carvedilol modified release formulation) to atenolol on indices of left ventricular dimensions when added to standardized angiotensin converting enzyme (ACE) inhibition, and to the effect of ACE inhibition alone. Subjects with LVH (left ventricular hypertrophy) and hypertension will be studied. The primary endpoint will be the change in left ventricular mass index (LVMI) characterized by magnetic resonance imaging (MRI) following 12 months of treatment. Secondary endpoints include the change in LV (left ventricular) mass, LV wall thickness, diastolic left ventricular filling parameters, and left ventricular ejection fraction by echocardiographic methods at Treatment Month 12. Composite outcomes and individual event data will also be evaluated by treatment group.
Condition | Intervention | Phase |
---|---|---|
Hypertension Left Ventricular Hypertrophy |
Drug: carvedilol MR Drug: atenolol Drug: lisinopril |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Parallel Assignment, Safety/Efficacy Study |
Official Title: | See Detailed Description |
Estimated Enrollment: | 220 |
Study Start Date: | January 2005 |
A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG MR) and Atenolol in Combination with and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Regression in Hypertensive Patients with Left Ventricular Hypertrophy (LVH).
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | COR100216 |
Study First Received: | April 13, 2005 |
Last Updated: | May 15, 2009 |
ClinicalTrials.gov Identifier: | NCT00108082 History of Changes |
Health Authority: | United States: Food and Drug Administration |
left ventricular hypertrophy (LVH) left ventricular mass regression left ventricular mass index (LVMI)hypertension cardiac MRI echocardiogram |
Pathological Conditions, Anatomical Hypertrophy, Left Ventricular Vasodilator Agents Neurotransmitter Agents Heart Diseases Adrenergic Agents Lisinopril Vascular Diseases Adrenergic alpha-Antagonists Cardiovascular Agents Antihypertensive Agents |
Protease Inhibitors Hypertrophy Angiotensin-Converting Enzyme Inhibitors Adrenergic beta-Antagonists Adrenergic Antagonists Anti-Arrhythmia Agents Peripheral Nervous System Agents Atenolol Cardiomegaly Hypertension Carvedilol |
Pathological Conditions, Anatomical Vasodilator Agents Neurotransmitter Agents Adrenergic Agents Molecular Mechanisms of Pharmacological Action Cardiotonic Agents Physiological Effects of Drugs Therapeutic Uses Angiotensin-Converting Enzyme Inhibitors Adrenergic beta-Antagonists Cardiovascular Diseases Anti-Arrhythmia Agents Carvedilol Hypertrophy, Left Ventricular Sympatholytics |
Heart Diseases Lisinopril Vascular Diseases Enzyme Inhibitors Adrenergic alpha-Antagonists Cardiovascular Agents Antihypertensive Agents Protective Agents Pharmacologic Actions Protease Inhibitors Hypertrophy Autonomic Agents Adrenergic Antagonists Peripheral Nervous System Agents Atenolol |